The linear progression through generations of BTK inhibitors may be a flawed strategy, as indefinite kinase blocking is unsustainable. The future likely lies in BTK degraders, a new drug class that eliminates the target protein entirely, offering a novel approach to overcoming resistance instead of just inhibiting the protein.

While second-generation BTK inhibitors are clinically similar, the next major advance in combination therapy may come from the BCL2 inhibitor component. The newer agent sonrotoclax is potentially more potent and selective than venetoclax, which could lead to superior efficacy and tolerability in future regimens.

Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.

When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.

The FLAIR trial provided the first clinical evidence that a time-limited combination of ibrutinib and venetoclax prevents the development of BTK resistance mutations. These mutations were observed in patients receiving continuous single-agent BTK inhibitor therapy, supporting a key theoretical advantage of time-limited combination approaches.

Using the non-covalent BTK inhibitor pirtobrutinib in the frontline setting poses a strategic risk. It can induce resistance mutations (e.g., T474I) that confer cross-resistance to both covalent and non-covalent BTK inhibitors, potentially eliminating an entire class of drugs for future use.

Modern therapies have dramatically improved survival for high-risk CLL patients. However, this group paradoxically represents the largest unmet need, as they are the most likely to develop resistance to the main drug classes over decades, driving research into novel mechanisms like degraders and non-covalent inhibitors.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

Unlike continuous BTK inhibitor therapy, using a BTK inhibitor as part of a time-limited combination regimen does not appear to select for resistance mutations. This crucial distinction means that a BTK inhibitor could potentially be used again effectively as a subsequent line of therapy if the patient relapses.